PsychoTropicalResearch, serotonin and serotonin syndrome research.

1. Ramsey, R R and Gillman, P K, Methylene Blue and Serotonin Toxicity: The Corroboration of a Theoretical Prediction. [In preparation], 2006.
Paper

2. Lawrence, K R, Adra, M and Gillman, P K, Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data. Clinical Infectious Diseases, 2006. 42: p. 1578-1583.
ReviewView abstract / article

3. Gillman, P K, A Review of the Pharmacology and Interactions of the Tricyclic Antidepressants. [Submitted], 2006.
Major review

4. Gillman, P K, Serotonin toxicity, serotonin syndrome: 2006 update, overview and analysis. 2006: p. Epub 1-125.
Major review View abstract / article

5. Gillman, P K, Extracting value from case reports: lessons from Serotonin toxicity. Anaesthesia, 2006. 61: p. 419-422.
EditorialView abstract / article

6. Gillman, P K, A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status. Human Psychopharmacology. Clinical and Experimental, 2006. 21: p. 117-125.
Major reviewView abstract / article

7. Gillman, P K, A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biological Psychiatry, 2006. 59: p. 1046-1051.
Major reviewView abstract / article

8. Gillman, P K, Drug interactions and fluoxetine: a Commentary from a clinician's perspective. Expert Opinion on Drug Safety, 2005. 4(6): p. 965-968.
EditorialView abstract / article

9. Gillman, P K, Understanding toxidromes: serotonin toxicity. A Commentary on Montanes-Rada et al. Journal of Clinical Psychopharmacology, 2005. 26: p. 625-626.
Comment, Mini reviewView abstract / article

10. Gillman, P K, Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 2005. 95: p. 434-441.
ReviewView abstract / article

11. Gillman, P K, Serotonin toxicity, serotonin syndrome: 2005 update, overview and analysis.2005.
Major Overview, e-pubView abstract / article

12. Gillman, P K, Mirtazapine: not a dual action antidepressant? Australian and New Zealand Journal of Psychiatry, 2004. 38(4): p. 266-267.
Letter, Comment

13. Gillman, P K, Making sense of serotonin toxicity reports. A Comment on Chopra et al. World Journal of Biological Psychiatry, 2004. 5: p. 166-167.
Comment, Mini review

14. Gillman, P K, Moclobemide and the risk of serotonin toxicity (or serotonin syndrome). Central Nervous System Drug Reviews, 2004. 10: p. 83-85.
Review, Comment

15. Gillman, P K, Commentary: clomipramine too soon after moclobemide. Review of Psychiatry, 1999. 4: p. 3-5.
Mini review

16. Gillman, P K, The serotonin syndrome and its treatment. Journal of Psychopharmacology, 1999. 13(1): p. 100-109.
Review

17. Gillman, P K, Serotonin Syndrome: History and Risk. Fundamental and Clinical Pharmacology, 1998. 12(5): p. 482-491.
Review

18. Gillman, P K, Serotonin syndrome: clomipramine too soon after moclobemide. International Clinical Psychopharmacology, 1997. 12: p. 339-342. Mini review

19. Gillman, P K, Successful treatment of serotonin syndrome with chlorpromazine. Medical Journal of Australia, 1996. 165: p. 345.
Letter

20. Curson, D A, Trauer, T, Bridges, P K and Gillman, P K, Assessment of outcome after psychosurgery using the Present State Examination. British Journal of Psychiatry, 1983. 143: p. 118-123.
Paper

21. Gillman, P K, Bartlett, J R, Bridges, P K, et al., Indolic substances in plasma, cerebrospinal fluid, and frontal cortex of human subjects infused with saline or tryptophan. Journal of Neurochemistry, 1981. 37(2): p. 410-417.
Paper

22. Gillman, P K, Bartlett, J and Bridges, P K, Selecting patients for psychosurgery. Biological Psychiatry, 1981. 16: p. 1090-1094.
Paper

23. Carter, S M, Glover, V, Sandler, M, Gillman, P K and Bridges, P K, Human platelet phenolsulphotransferase: separate control of the two forms and activity range in depressive illness. Clinica Chimica Acta, 1981. 117(3): p. 333-344.
Paper

24. Gillman, P K, Bartlett, J R, Bridges, P K, Kantamaneni, B D and Curzon, G, Relationships between tryptophan concentrations in human plasma, cerebrospinal fluid and cerebral cortex following tryptophan infusion. Neuropharmacology, 1980. 19(12): p. 1241-1242.
Paper

25. Curzon, G, Kantamaneni, B D, Van Boxel, P, et al., Substances related to 5-hydroxytryptamine in plasma and in lumbar and ventricular fluids of psychiatric patients. Acta Psychiatrica Scandinavica, 1980. 280: p. 3-20.
Paper

26. Carter, S M, Goodwin, B L, Sandler, M, Gillman, P K and Bridges, P K, Decreased conjugated tyramine output in depression: the effect of oral L-cysteine. British Journal of Clinical Pharmacology, 1980. 10(3): p. 305-308.
Paper

27. Gaind, R, Gillman, P K and Taylor, P, Alpha-methyldopa in schizophrenia. Journal of Clinical Psychiatry, 1978. 39(11): p. 815-816.
Paper

28. Gillman, P K, Misleading cases. Journal of the American Medical Directors Association, 2005. 6: p. 422-423.
CommentView abstract / article

29. Gillman, P K, The serotonin syndrome. New England Journal of Medicine, 2005. 352(23): p. 2454-2456.
CommentView abstract / article

30. Gillman, P K, Non-science and nonsense, without refutation. Public Library of Science: Medicine, 2005: p.
Letter, CommentView abstract / article

31. Gillman, P K, NMS and ST: chalk and cheese. British Medical Journal, 2005: p.
Letter, CommentView abstract / article

32. Gillman, P K, Signing the script. Australian Prescriber, 2005. 28: p. 29.
CommentView abstract / article

33. Gillman, P K and Whyte, I M, Serotonin syndrome. Adverse Syndromes and Psychiatric Drugs, ed. Haddad, P, Dursun, S, and Deakin, B. 2004, Oxford: Oxford University Press. 37-49.

34. Gillman, P K, Re: no evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Human Psychopharmacology. Clinical and Experimental, 2004. 20(1): p. 61-62.
Letter,Comment, Mini reviewView abstract / article

35. Gillman, P K, Serotonin toxicity. www.depression-webworld.com, 2004: p.
Mini review, e-pub

View abstract / article

36. Gillman, P K, Reply to associate professor Norman. Australian and New Zealand Journal of Psychiatry, 2004. 38(4): p. 269.
CommentView abstract / article

37. Gillman, P K, Comment on "Serotonin syndrome due to coadministration of linezolid and venlafaxine" by Jones et al. Journal of Antimicrobial Chemotherapy, 2004. 54: p. 844-845.
Letter, Comment

38. Gillman, P K, Defining toxidromes: serotonin toxicity and neuroleptic malignant syndrome: A Comment on Kontaxakis et al. Archives of General Hospital Psychiatry, 2004: p.
Mini review, e-pub

View abstract / article

39. Gillman, P K, Serotonin toxicity [electronic response to Perry NK; Venlafaxine-induced serotonin syndrome with relapse following amitriptyline]. Postgraduate Medical Journal, 2004: p.
CommentView abstract / article

40. Gillman, P K, The spectrum concept of serotonin toxicity. Pain Medicine, 2004. 5: p. 231-232.
Letter, Comment, Mini review

41. Gillman, P K, Fifty years of poor science. British Journal of Psychiatry, 2003: p.
Comment, e-pubView abstract / article

42. Gillman, P K, Mirtazapine: unable to induce serotonin toxicity? Clinical Neuropharmacology, 2003. 26: p. 288-289.
CommentView abstract / article

43. Gillman, P K, Serotonin toxicity and 5-HT2A receptors. Current Psychiatry (Online), 2003. 2: p.
CommentView abstract / article

44. Gillman, P K, Prayer study defects. Skeptical Inquirer, 2003. 23: p. 67.
Comment

45. Gillman, P K, Serotonin syndrome. Australian Prescriber, 2003. 26: p. 100-101.
Comment

46. Gillman, P K, Linezolid and serotonin toxicity. Clinical Infectious Diseases, 2003. 37: p. 1274-1275.
Comment

47. Gillman, P K, Amitriptyline: Dual-Action Antidepressant? Journal of Clinical Psychiatry, 2003. 64: p. 1391.
Comment

48. Gillman, P K, Reply to: Clinical interview Serotonin syndrome. Australian medicine, 2001. Oct: p. 71.
Letter

49. Gillman, P K, Limits in drug assessment. Skeptical Inquirer, 2001. 25(4): p. 77.
Letter

50. Gillman, P K, Cytochrome P450 enzyme interactions. Australian Prescriber, 2001. 24(4): p. 80.
Comment

51. Gillman, P K, Clinical interview: Serotonin syndrome. Australian medicine, 2001. August: p. 5-6.
Interview

52. Gillman, P K, Comments on "Serotonin syndrome during treatment with paroxetine and risperidone". Journal of Clinical Psychopharmacology, 2001. 21(3): p. 344-345.
CommentView abstract / article

53. Gillman, P K, Relative value of bupropion. Australian Medicine, 2001. 13: p. 7.
Letter

54. Gillman, P K, Serotonin syndrome. Psychiatric Bulletin of the Royal College of Psychiatrists, 2000. 24: p. 197.
Letter

55. Gillman, P K, Paradoxical pattern of haematological risk with clozapine. British Journal of Psychiatry, 2000. 177: p. 88.
Letter, Comment

56. Gillman, P K, Relative toxicity of antidepressants. Australian and New Zealand Journal of Psychiatry, 1999. 33: p. 444.
Comment

57. Gillman, P K, Relative effectiveness and safety of antidepressants. Drug Wise, 1999. 23: p. 20.
Comment

58. Gillman, P K and Hodgens, S, Serotonin syndrome following SSRI mono-therapy. Human Psychopharmacology. Clinical and Experimental, 1998. 13: p. 525-526.
Letter, Mini review

59. Gillman, P K, Serotonin syndrome treated with chlorpromazine. Journal of Clinical Psychopharmacology, 1997. 17: p. 128-129.
Letter

60. Gillman, P K, Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Medical Journal of Australia, 1997. 167: p. 109-111.
Letter

61. Gillman, P K, Tacrine for treatment of sleep disturbance in dementia. Journal of the American Geriatrics Society, 1997. 45(10): p. 1286.
Letter

62. Gillman, P K, Scepticism about health care claims. Sceptical Inquirer, 1997. 17: p. 34.
Letter

63. Gillman, P K, Serotonin syndrome: It's older than you think. Drug Wise, 1996. 20(5): p. 59.
Comment

64. Gillman, P K, The new antidepressants. Australian Prescriber, 1996. 19(2): p. 37-38. Letter

65. Gillman, P K, Possible serotonin syndrome with moclobemide and pethidine. Medical Journal of Australia, 1995. 162: p. 554.
Letter

66. Gillman, P K, Plus ça change, plus c'est la même chose. Pharmabulletin, 1994. 18(1): p. 10-11.
Comment

67. Gillman, P K, MAOIs and dangerousness. Australian Prescriber, 1994. 17(2): p. 29.
Letter

68. Gillman, P K, Fluoxetine (Prozac). Medical Journal of Australia, 1993. 159(7): p. 492.
Letter

69. Gillman, P K, Safety of MAOIs and side effects clomipramine. Pharmabulletin, 1990. 14: p. 15.
Letter

70. Gillman, P K, Latitude and affective disorders. British Journal of Psychiatry, 1987. 151: p. 276.
Letter

71. Gillman, P K, Playing dice with the expert evidence. Medical Journal of Australia, 1987. 147: p. 532.
Letter

72. Gillman, P K, Monoamineoxidase inhibitors. Current Therapeutics, 1984. 43: p. 79.
Letter

73. Gillman, P K, The team approach. British Journal of Psychiatry, 1977. 141: p. 276.
Letter